Related Experiment Videos
Pyridoxine in atopic dermatitis
D C Mabin1, S Hollis, J Lockwood
1Department of Child Health, University of Manchester, Booth Hall Children's Hospital, Blackley, U.K.
Insights
Pyridoxine hydrochloride (vitamin B6) supplementation did not show significant benefits for children with atopic dermatitis. This randomized trial found no improvement in clinical severity or symptoms compared to placebo.
Area of Science:
- Dermatology
- Clinical Nutrition
- Pediatrics
Background:
- Previous research suggested potential benefits of pyridoxine hydrochloride for atopic dermatitis.
- Atopic dermatitis is a common inflammatory skin condition in children.
- The efficacy of pyridoxine supplementation in pediatric atopic dermatitis requires further investigation.
Purpose of the Study:
- To evaluate the clinical effectiveness of pyridoxine hydrochloride in children with moderate to severe atopic dermatitis.
- To assess the impact of pyridoxine supplementation on disease activity and symptoms.
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted.
- Forty-eight children with atopic dermatitis were enrolled.
- Participants received either pyridoxine hydrochloride (50 mg daily) or placebo for 4 weeks, with outcomes assessed via clinical severity and symptom scores.
Main Results:
- No statistically significant differences in clinical severity scores were observed between the pyridoxine hydrochloride and placebo groups.
- Parent-reported symptom scores for itch and sleep disturbance also showed no significant improvement with pyridoxine supplementation.
- The study did not demonstrate a clinical benefit of pyridoxine hydrochloride in this pediatric cohort.
Conclusions:
- Pyridoxine hydrochloride supplementation at 50 mg daily for 4 weeks did not prove effective in treating moderate to severe atopic dermatitis in children.
- Further research may be needed to explore alternative dosages or specific subgroups, but current evidence does not support its use.
- This study failed to replicate previous findings of benefit in a pediatric population.
Abstract:
A previous study has reported benefit when pyridoxine hydrochloride was given to patients with atopic dermatitis. To investigate this in children, we performed a randomized, double-blind, parallel-group, placebo-controlled trial. Forty-eight children with moderate or severe atopic dermatitis were recruited and, of those who completed the study, 19 received pyridoxine hydrochloride 50 mg once daily for 4 weeks and 22 received placebo. Disease activity was monitored by clinical severity scores measuring the extent and degrees of erythema recorded by the investigator and symptom scores (daytime itch and nocturnal sleep disturbance) recorded by parents. There was no statistically significant difference between the two groups at the end of treatment. We have been unable to demonstrate clinical benefit from pyridoxine supplementation in children with atopic dermatitis.